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Abstract
Background: Few studies of microbicide acceptability among HIV-infected women have been done. We assessed
CarraguardH vaginal gel acceptability among participants in a randomized, controlled, crossover safety trial in HIV-infected
women in Thailand.
Methodology/Principal Findings: Participants used each of 3 treatments (Carraguard gel, methylcellulose placebo gel, and no
product) for 7 days, were randomized to one of six treatment sequences, and were blinded to the type of gel they received in the
two gel-use periods. After both gel-use periods, acceptability was assessed by face-to-face interview. Responses were compared to
those of women participating in two previous Carraguard safety studies at the same study site. Sixty women enrolled with a
median age of 34 years; 25% were sexually active. Self-reported adherence (98%) and overall satisfaction rating of the gels (87%
liked ‘‘somewhat’’ or ‘‘very much’’) were high, and most (77%) considered the volume of gel ‘‘just right.’’ For most characteristics,
crossover trial participants evaluated the gels more favorably than women in the other two trials, but there were few differences in
the desired characteristics of a hypothetical microbicide. Almost half (48%) of crossover trial participants noticed a difference
between Carraguard and placebo gels; 33% preferred Carraguard while 12% preferred placebo (p=0.01).
Conclusions/Significance: Daily Carraguard vaginal gel use was highly acceptable in this population of HIV-infected
women, who assessed the gels more positively than women in two other trials at the site. This may be attributable to higher
perceived need for protection among HIV-infected women, as well as to study design differences. This trial was registered in
the U.S. National Institutes of Health clinical trials registry under registration number NCT00213044.
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Introduction
The development of a safe, effective topical microbicide for
HIV prevention is a major public health priority [1]. Over 40
compounds are being evaluated as topical vaginal microbicides,
including 12 products currently in clinical trials [2]. Microbicides
are intended for use by women at risk of sexually transmitted HIV,
but once marketed they may also be used by HIV-infected women
either because they are unaware of their HIV status, to protect
themselves against other sexually transmitted infections (STI), or to
prevent HIV transmission to a sex partner.
The eventual uptake and consistent use of microbicides will
depend on their acceptability among both women and men, and
acceptability data are critical to inform both product formulation
and social marketing messages [3]. Despite a rapidly growing
literature on microbicide acceptability, there have been few studies
among HIV-infected women [3-9]. We report acceptability results
from a safety trial with crossover design of CarraguardH vaginal
gel among HIV-infected women in Chiang Rai, Thailand, and
present a comparison with acceptability data from two previous
Carraguard trials at the same site.
A recently completed phase III trial of Carraguard did not
demonstrate efficacy in preventing HIV acquisition [10], but
combination products including Carraguard and anti-retroviral
drugs are currently under development at the Population Council.
Acceptability findings regarding Carraguard may therefore be
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for other gels with similar properties.
Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki, and was approved by the
Institutional Review Boards of the Population Council, Centers
for Disease Control and Prevention, and the Ethical Review
Committee of the Thailand Ministry of Public Health. Written
informed consent was obtained from all study participants. The
protocol for this trial is available as supporting information; see
Protocol S1.
Study design
Acceptability data were collected as part of a 3-month,
randomized, placebo-controlled crossover trial conducted to
evaluate the safety and acceptability of Carraguard among HIV-
infected women (hereafter referred to as ‘‘crossover trial’’). Each
woman participated in each of 3 study interventions (Carraguard,
methylcellulose placebo, and no product) over three consecutive
months with the order of interventions randomly assigned. When
using study gels, women were blinded to the type of gel they
received. Carraguard and placebo are both clear and odorless gels
packaged in a single-use MicrolaxH-type applicator (Norden Pac
International AB, Kalmar, Sweden). This applicator was shown in
previous studies to dispense about 5 ml of gel [11]. Participants
attended the clinic at day 0, 7, and 14 of each study month for
interview, examination and specimen collection. They were asked
to apply study gel vaginally once daily for 7 days starting after
menses were completed (day 0) during the two gel months. Full
methods and safety findings are reported in detail elsewhere [12].
Study population
Women were recruited from HIV care clinics and support
groups in five districts of Chiang Rai province in northern
Thailand. Eligibility criteria included aged 18-50 years; CD4+ cell
count 51–500/mm
3; not currently on antiretroviral therapy
(ART); and either being sexually abstinent or having a single
male partner who was confirmed HIV-infected and aged 18 years
or older. At study initiation, eligibility for ART in public clinics
was limited; women were referred for ART at the time of study
screening and encouraged to initiate ART as soon as available,
regardless of study participation. During the study, eligibility
expanded substantially and all eligible women accessed ART
during or shortly after the study.
Acceptability data collection
After completing both gel-use periods, women completed an
interviewer-administered questionnaire that included both struc-
tured and open-ended questions about the participants’ views on
product attributes and use of the gels. Most of these questions
addressed both gels simultaneously, as previous studies had shown
no difference in acceptability responses between Carraguard and
placebo groups [13,14]. However, the previous studies were
traditional parallel arm studies in which participants were
randomized to either Carraguard or placebo. Since this crossover
trial was the first time that individual women used both
Carraguard and placebo, additional questions asked women to
compare the two gels they had used. At the time these questions
were asked, the women did not yet know which of the two gels was
Carraguard and which was placebo. Adherence was assessed by
participant self-report in face-to-face interviews and by counting
returned used and unused applicators (returned in separate bags).
Data analysis
Data were double-entered into an Access database (Microsoft,
Inc., Redmond, Washington, USA). Codes for open-ended
questions were initially developed by trial staff and were reviewed
and revised by staff members at the Population Council in New
York City. Data were analyzed using SAS statistical software
package (SAS version 9.1, SAS Institute, Cary, North Carolina,
USA). Chi-square tests were used to evaluate differences between
groups.
Comparison with previous Carraguard studies in Thailand
Some acceptability questions in the crossover trial were asked in
an identical manner in two previous studies of Carraguard safety
and acceptability at the same site in Thailand; for these questions,
comparisons are presented here. The first study was conducted to
assess safety and acceptability among 165 low-risk, HIV-uninfected
women followed for one year (hereafter referred to as ‘‘phase II
trial’’)[14,15]. Participants were asked to apply Carraguard or
placebo once per day in the evening, and if sex took place, within
one hour before sex together with condoms; 98% of participants
weremarriedandsexuallyactive.Thesecondstudyenrolled55low-
risk, HIV-uninfected, sexually active couples for 6 months,
primarily to assess safety of exposure during intercourse and
acceptability among male partners; safety and acceptability among
female participantswere alsoevaluated [13,16]. Couples were asked
to apply Carraguard or placebo within one hour before sex;
condoms and counseling were provided but condoms were rarely
used in the trial. We present acceptability responses from female
participants in the phase II and couples trials concurrently with
results of the crossover trial for comparison.
Results
Crossover study population
Between 2002 and 2004, 222 women were screened and 60
were enrolled in the trial; one woman was lost to follow up after
she completed the acceptability assessment. Enrolled women had a
median age of 34 years, had been diagnosed with HIV a median of
44 months previously, and had a median CD4+ lymphocyte count
of 296 cells/mL (Table 1). Seventeen (28%) women were married,
with the remainder either widowed (60%) or divorced (12%). The
15 (25%) women who were sexually active at the time of the trial
reported having had sex a median of 4 times in the previous
month, and median condom use in the previous month was 4
times. No participants reported anal or oral sex in the previous
month.
Adherence
Reported adherence to gel use was high, with 59 (98%) women
using at least 6 of 7 scheduled doses during each gel use period.
Only one woman interrupted gel use for reasons unrelated to
adverse effects.
Acceptability
Overall satisfaction rating of the gels was high, with 22 (37%) and
30 (50%) participants reporting they liked the gel ‘‘very much’’ and
‘‘somewhat,’’ respectively, and 60 (100%) stating they would
recommend it to a friend (Table 2). Most participants described
the applicator as appealing (72%) or neutral (25%), and found the
gel easy to apply (83%). The gel volume was assessed as ‘‘just right’’
by 46 (77%) women and ‘‘too much’’ by 14 (23%), while 55 (92%)
Carraguard Acceptability
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advantage. Only 17 (28%) women believed that it would be
possible to use gel without their partner being aware. In response to
open-ended questions about how they would change the product if
they could, 45 women had no suggested changes, 12 suggested
softening the applicator tip, and 10 suggested a smaller gel volume.
Acceptability responses varied among the three Thai safety trial
populations for most characteristics (Table 2). For example, there
was a significant difference among groups in the overall satisfaction
rating of gel; more women in the crossover trial said they ‘‘liked the
gel very much’’ compared to women in the other two studies. There
were also differences in the proportion of women considering covert
use possible, and judging the volume of gel as too much. For most
parameters, participants in the crossover trial evaluated the gels
more favorably than those in the other two trials.
Desired characteristics of a microbicide
Crossover trial participants rated the following characteristics as
most important in a microbicide: the partner being unable to tell gel
is there (77% very important, 15% somewhat important), being
personally unable to tell gel is there (73% very important, 13%
somewhat important), providing extra lubricant (58% very impor-
tant, 37% somewhat important), and making the vagina feel tight
(57% very important, 30% somewhat important) (Table 3). There
were statistically significant differences among the 3 trial populations
for only three of the ten microbicide characteristics assessed: extra
lubricant, giving a warm feeling, and having a good taste.
Table 1. Baseline demographic, behavioral, and clinical
characteristics.
Characteristic
Participants
(N=60)
Age in years, median (Q1–Q3) 34 (30–40)
Marital status
Widowed 36 (60%)
Married 17 (28%)
Separated/Divorces 7 (12%)
Ever accepted money/gifts for sex 8 (13%)
Any vaginal product use in past month 10 (17%)
Vaginal sex in past month
1 15 (25%)
If sex, number of sex acts last mo, median (Q1–Q3) 4 (2–9)
If sex, times condom used last mo, median (Q1–Q3) 4 (2–6)
Current use of contraception
2 30 (50%)
Years since first HIV+ test, median (Q1–Q3) 4.6 (2.7–7.1)
CD4 cell count, median (Q1–Q3) 296 (168–349)
Plasma HIV viral load (log10 copies/ml), median (Q1–Q3) 4.6 (4.1–5.2)
1No anal or oral sex reported.
2Although only 25% of participants were sexually active at the time of the trial,
women who had a permanent method of contraception are also reported as
current contraceptive users.
doi:10.1371/journal.pone.0014831.t001
Table 2. Carraguard and placebo gel acceptability among HIV-positive and negative women in 3 trials in Chiang Rai, Thailand
1.
HIV-positive women,
crossover trial
HIV-negative women,
phase II trial
HIV-negative women,
couples trial
2003–2004 2000–2001 2001–2002
Characteristic N=60 N=157 N=54 p-value
Overall satisfaction rating of gel ,0.0001
Liked very much 22 (37%) 18 (12%) 12 (22%)
Liked somewhat 30 (50%) 87 (55%) 38 (70%)
Neutral 4 (7%) 48 (31%) 4 (7%)
Disliked some/very much 4 (7%) 4 (2%) 0
Would recommend gel to a friend 60 (100%) 157 (100%) 54 (100%) –
Volume of gel ,0.0001
Too much 14 (23%) 97 (62%) 29 (55%)
Just right 46 (77%) 59 (38%) 24 (45%)
Not enough 0 1 (1%) 0
Applicator 0.02
Appealing 43 (72%) 77 (49%) 28 (52%)
Neutral 15 (25%) 73 (46%) 26 (48%)
Unappealing 2 (3%) 7 (4%) 0
Ease of gel application 0.002
Somewhat/very easy 50 (83%) 101 (64%) 34 (63%)
Neutral 10 (17%) 51 (32%) 19 (35%)
Somewhat/very difficult 0 5 (3%) 1 (2%)
Extra lubrication an advantage 55 (92%) 117 (74%) 52 (96%) ,0.0001
Covert use possible 17 (28%) 71 (45%) 9 (17%) 0.0003
1Acceptability responses are presented from the visit after completion of 2 gel use periods for participants in the crossover trial, and from the closing visit for the phase
II and couples trials.
doi:10.1371/journal.pone.0014831.t002
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trial participants
Almost half of crossover trial participants (48%) reported that
they noticed a difference between the Carraguard and placebo gels
(Table 4). Among the 29 women who reported a difference, 15
reported on open-ended questioning that placebo gel leaked more,
6 that placebo felt more viscous, 5 that Carraguard felt more
natural, and 4 that Carraguard felt more viscous. A total of 20
(33%) women preferred Carraguard while 7 (12%) preferred
placebo (p=0.01), with no significant difference by order of gel
received. Most women who preferred Carraguard over placebo
did so because they perceived that it was less messy (12 responses)
Table 3. Desired product characteristics reported by HIV-positive and negative women in 3 trials in Chiang Rai, Thailand.
Crossover trial (HIV-
positives)
Phase II trial (HIV-
negatives)
Couples trial (HIV-
negatives)
2003–2004 2000–2001 2001–2002
Characteristic N=60 N=157 N=54 p
Extra lubricant 0.0004
Very important 35 (58%) 65 (41%) 32 (59%)
Somewhat important 22 (37%) 56 (36%) 20 (37%)
Not important 2 (3%) 36 (23%) 2 (4%)
Dries vagina 0.12
Very important 1 (2%) 19 (12%) 2 (4%)
Somewhat important 4 (7%) 8 (5%) 5 (9%)
Not important 55 (92%) 128 (82%) 46 (85%)
Gives warm feeling 0.005
Very important 10 (17%) 9 (6%) 5 (9%)
Somewhat important 19 (32%) 33 (21%) 22 (41%)
Not important 30 (50%) 114 (73%) 26 (48%)
Makes vagina feel tight 0.21
Very important 34 (57%) 88 (56%) 23 (43%)
Somewhat important 18 (30%) 35 (22%) 21 (39%)
Not important 8 (13%) 32 (20%) 10 (18%)
Cannot tell gel is there 0.17
Very important 44 (73%) 92 (59%) 31 (57%)
Somewhat important 8 (13%) 15 (28%) 15 (28%)
Not important 8 (13%) 19 (12%) 8 (15%)
Partner cannot tell gel is there 0.25
Very important 46 (77%) 108 (69%) 33 (61%)
Somewhat important 9 (15%) 39 (25%) 16 (30%)
Not important 4 (7%) 10 (6%) 5 (9%)
Slows time to ejaculation 0.13
Very important 11 (18%) 23 (15%) 12 (22%)
Somewhat important 16 (27%) 29 (18%) 18 (33%)
Not important 33 (55%) 104 (66%) 24 (44%)
Speeds time to ejaculation 0.77
Very important 17 (28%) 34 (22%) 10 (18%)
Somewhat important 16 (27%) 49 (31%) 17 (32%)
Not important 27 (45%) 74 (47%) 27 (50%)
Smells good 0.49
Very important 27 (45%) 64 (41%) 17 (32%)
Somewhat important 17 (28%) 44 (28%) 23 (43%)
Not important 16 (27%) 48 (31%) 14 (26%)
Tastes good 0.002
Very important 19 (32%) 15 (10%) 5 (9%)
Somewhat important 11 (18%) 40 (26%) 10 (18%)
Not important 29 (48%) 100 (64%) 39 (72%)
doi:10.1371/journal.pone.0014831.t003
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reported leakage or messiness (16 responses) as their least liked
feature.
Role of microbicides for HIV-infected women
When asked what role microbicides might play for them as
HIV-infected women, participants most commonly responded that
microbicides could protect them from infection with another strain
of HIV or other STI (51 responses), and that it might protect their
partner from HIV acquisition (13 responses). On the other hand,
when asked, ‘‘If microbicides provided the same protection as
condoms, do you think men would be less willing to use
condoms?’’ 57 (95%) women responded yes. A majority of women
(68%) reported being willing to pay at least the equivalent price as
condoms for a microbicide.
Discussion
Overall acceptability of study gels was high among this
population of HIV-infected women. Our findings contribute to
the small body of literature evaluating the acceptability of
microbicide candidates among HIV-infected women [4,7,8,17].
Acceptability responses of women in this crossover trial were
broadly positive, as they were among women in two previous
Carraguard safety studies in the same northern Thai community
and in a similar trial including HIV-infected women in Durban
[7]. Although the questions were not identical between the trials,
similar proportions of HIV-infected women participants in Chiang
Rai and Durban reported they liked the product (87% in Chiang
Rai vs. 93% in Durban) and believed it could be used covertly
(28% and 30% respectively). Given the known regional differences
in preferences for vaginal lubrication during sex [18], it is not
surprising that there were also differences between the Thai and
South African participants in the importance assigned to a
microbicide that provides extra lubrication (95% in Chiang Rai
vs. 69% in Durban) and that dries the vagina (9% vs. 41%).
In comparing responses of women in the crossover trial to those of
the other two Carraguard trials at the Chiang Rai site, women in the
crossover trial rated the study gels more positively than women in the
other studies for most characteristics. This may be partly attributable
Table 4. Comparisons between Carraguard and placebo gels by HIV-positive women in the crossover trial, Chiang Rai, Thailand.
All participants
Carraguard-placebo
sequence
1 Placebo-Carraguard sequence
2
Question N=60 N=30 N=30
Noticed a difference between gels 29 (48%) 17 (57%) 12 (40%)
Gel preferred
3
Carraguard 20 (33%) 12 (40%) 8 (27%)
Placebo 7 (12%) 4 (13%) 3 (10%)
No preference/no difference 33 (55%) 14 (47%) 19 (63%)
Most common differences reported
4
Placebo leaked more 15 (25%) 5 (17%) 10 (33%)
Placebo more viscous 6 (10%) 3 (10%) 3 (10%)
Carraguard felt more natural 5 (8%) 1 (3%) 4 (13%)
Carraguard more viscous 4 (7%) 0 4 (13%)
1Includes women randomized to the following sequences: Carraguard-placebo-no gel; Carraguard-no gel-placebo; and no gel-Carraguard-placebo. Women in the gel
use groups were blinded to the type of gel they received.
2Includes women randomized to the following sequences: placebo-Carraguard-no gel; placebo-no gel-Carraguard; and no gel-placebo-Carraguard. Women in the gel
use groups were blinded to the type of gel they received.
3The difference between the number of women preferring Carraguard over placebo was statistically signficant with p=0.01; there was no significant difference in gel
preference by randomization sequence.
4Responses are from open-ended questions.
doi:10.1371/journal.pone.0014831.t004
Table 5. Open-ended comments regarding gel preferences by crossover trial participants
1.
Preferred Carraguard (n=20) Preferred placebo (n=7)
Best liked features Less messy (12 responses) Less messy (3 responses)
Natural/no sensation (9 responses) Natural/no sensation (2 responses)
Lubrication (5 responses) Lubrication (2 responses)
Least liked features Leakage/messiness (8 responses) Leakage/messiness (16 responses)
Too sticky/viscous (1 response) Too sticky/viscous (5 responses)
Too much volume (3 responses)
Too wet/too watery (3 responses)
1Total responses do not add up to the number of women with preference for one gel (n=27) because some women gave more than one response to each question.
doi:10.1371/journal.pone.0014831.t005
Carraguard Acceptability
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personal experience of the impact of HIV disease may make women
moreenthusiasticabout preventiontechnologiesandmore tolerantof
inconveniences of product use such as leakage [17]. However,
important differences in participant characteristics, trial design,
duration, and study requirements are also likely to have contributed
to the different responses. In particular, participants in the phase II
and couples trials were in long-term, stable partnerships compared to
only a quarter of participants in the crossover trial; consistent condom
use concurrent with microbicide use was strongly counselled in the
phase II study and crossover studies but not in the couples study; and
the duration of product use varied from one year in the phase II trial
and 6 months in the couples trial to two one-week periods in the
crossover trial. There was evidence in both the phase II and the
couples studies that acceptability responses changed over time
[13,14]. The observed differences in acceptability responses among
these three trials of the same product in the same community and
cultural context suggests that differences in study design and context
of use are important contributors to womens’ responses to a product.
This suggests that even if standardized acceptability measures are
used, comparisons of the acceptability of a candidate microbicide in
different populations, or comparison of different microbicide
candidates, must be interpreted with great caution.
A unique feature of the crossover trial was that, by design, each
participant used both Carraguard and placebo gel. Carraguard
and its methylcellulose placebo were both clear and odorless gels
packaged in identical opaque applicators, but due to differences in
the rheological properties of the two compounds the placebo had
somewhat lower viscosity and may show other differences in
rheological properties in the face of shear stress. About half the
women in this trial noticed a difference between the two gels, and
most of these women preferred Carraguard over placebo. Placebo
was more commonly reported to cause leakage, and Carraguard
was described as less messy and as feeling more natural. These
findings suggest that even relatively subtle differences in the
biophysical properties of candidate microbicide gels are perceived
by at least some women. There may be an optimal set of such
properties with respect to product acceptability, which should be
considered alongside the vaginal coating and distribution consid-
erations that currently inform formulation science early in the
product development cycle [9,19,20].
Our study had a number of limitations. This small, single-site
safety trial enrolled a group of highly motivated participants who
met multiple inclusion criteria, and thus results may not be
representative of HIV-infected women in the broader community.
Participants used gel for only two seven-day periods, and applied it
once daily in the evening rather than before sex which may more
closely simulate eventual recommended use of the product
(although antiretroviral-based microbicides may be developed for
daily rather than pre-coital use). Participants were strongly
counseled to use condoms consistently during the trial, so
acceptability responses for sexually active participants reflect
concurrent gel and condom use only, rather than gel use alone. In
addition, only a quarter of the study population was sexually active
during the trial, so many responses related to gel use during sex
were hypothetical. Finally, acceptability data were collected in
face-to-face interviews which may have led to social desirability
biases in women’s responses.
Although topical microbicides currently under development are
intended for use by HIV-uninfected women, the HIV-infected
women participating in this trial identified an interest and need for
microbicides, including protection against other STI and protection
of partners from HIV infection. With the current focus on and
promise of antiretroviral-based microbicides [22], the potential
utility of non-antiretroviral microbicides for STI protection in both
HIV-infected and uninfected women should remain under
consideration and research planned accordingly. On a cautionary
note, most trial participants believed an effective microbicide would
make men less likely to use condoms; this concerning finding was
also reported by Ramjee et al. [7] and suggests that educational and
marketing messages will need to be carefully tailored around
hierarchies of risk, especially in high-HIV prevalence settings.
It has been recommended that microbicide candidate product
safety be demonstrated among HIV-infected women before
widespread marketing [21]. Safety trials such as this one therefore
offer an ideal opportunity to assess microbicide acceptability prior
to introduction, so that potential microbicide uses and marketing
messages associated with microbicides among women living with
HIV and their partners can be considered.
Supporting Information
Protocol S1 Trial protocol.
Found at: doi:10.1371/journal.pone.0014831.s001 (0.48 MB
DOC)
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